The Business of Biotech was back in San Francisco for JPM in January, and offers here a few observations, highlights, and ...

There is more than one way to blockbuster product sales, and sometimes smaller might be better, writes Bennett Smith.

Raw authenticity can be disruptive in life sciences workplaces, but learning corporate fluency and stylistic pivots can help leaders become strategically authentic, writes Hope Mueller.

Pushing boundaries, staying grounded, and having fun along the way are the key ingredients for success in biotech, writes ...

Empirical research comparing corporate and academic spin-offs consistently shows that corporate-originated ventures outperform their academic counterparts in terms of growth and survival. This ...

The well-worn adage “good companies are bought, not sold” suggests that top-tier businesses, especially in high-growth industries like life sciences, do not need to seek buyers; instead, buyers pursue ...

Since the start of his second term, President Trump has shown a clear commitment to improving access to medicines for American patients. In late September 2025, his Administration reaffirmed this ...

As the life sciences industry grapples with the demands of AI and the need to integrate real-world evidence into increasingly complex pipelines, the FAIR data principles — Findable, Accessible, ...

Biotechnology is all about scientific breakthroughs that lead to transformative therapies. But despite billions invested and years of R&D, data from Deloitte found that more than half of drug launches ...

Amid recent and proposed sweeping cuts to federal research funding, ranging from suspended federal funding to universities and research facilities to updated policy by the NIH (NIH) to reduce indirect ...

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...